ClinicalTrials.gg
CompletedNCT03421457Updated Mar 18, 2019

Laparoscopic Lateral Suspension With Mesh & Sacrocervicopexy for the Treatment of Uterine Prolapse

An interventional study of Uterus-preserving laparoscopic lateral suspension with mesh and Uterus-preserving laparoscopic sacrocervicopexy with mesh in Pelvic Organ Prolapse and Pelvic Floor Prolapse, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Completed at 2 sites in Turkey. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-18.

Primary conditionUterine ProlapseRegistry: Pelvic Organ ProlapseReclassifiedWhy we changed it
Registry
Pelvic Organ Prolapse — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Prolapse
Why
  1. The study's title name Uterine Prolapse, a narrower term within Pelvic Organ Prolapse.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study is aimed to compare the efficiency of two uterus-preserving laparoscopic methods to treat uterine prolapse in a randomized controlled trial. Laparoscopic lateral suspension with mesh (LLSM) will be compared with laparoscopic sacrohysteropexy (LS). Both procedures are known as sufficient uterus preserving methods. LLSM was introduced to be an alternative to others with avoiding dissection of promontory and therefore being safer, faster and feasible technique.

Read the detailed description

Patient with uterine prolapse can participate in this study. A total of 44 women will be included. At random 22 patients undergo laparoscopic lateral suspension with mesh operation and 22 patients undergo laparoscopic sacrohysteropexy operation. Evaluation will take place during the surgery, at the postoperative visit after 4 weeks, 6th months and 12th months. Quality of life, degree of vaginal prolapse, safety, operation time and complications will be evaluated.

Subjective assessments will include Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS).

Objective assessments will include routine gynecologic sonography, Pelvic Organ Prolapse Quantification System (POP-Q) and pelvic floor biometry measured by transperineal sonography.

Transperineal sonography will include those measurements:

Urethral rotation, Pelvic organ descent, Hiatal Diameter and the Anatomical localization of apex.

02

Conditions studied

  • Pelvic Organ Prolapse
  • Pelvic Floor Prolapse

Browse trials for

Keywords

  • Pelvic Organ Prolapse
  • Translabial ultrasound
  • Transperineal ultrasound
  • Lateral Mesh Suspension
  • Descensus uteri
  • Laparoscopic pelvic organ prolapse repair
  • Uterus preserving
  • hysteropexy
  • uterine-preserving
  • fertility-sparing
  • sacropexy
  • cervicopexy
  • sacrocervicopexy
  • sacrohysteropexy
  • mesh prolapse surgery
03

In context

Uterine Prolapse Reclassified

111 studies on the registry are indexed under Uterine Prolapse; 18 are open to participants now.

This study's enrollment of 44 is below the median of 70 across 76 interventional studies indexed under Uterine Prolapse.

Browse Uterine Prolapse studies →

Lead sponsor

Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 120 studies on the registry; 33 are open to participants now.

Compared within Uterine Prolapse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pelvic Organ Prolapse. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years old
  • > Symptomatic prolapse of central compartment with a Pelvic Organ Prolapse Quantitative (POP-Q) stage 2 associated or not with anterior or posterior compartment prolapse.
  • Patients who are not comfortable with using or refusing pessary
  • Wish to preserve the uterus

Exclusion criteria

Exclusion Criteria:

  • Any cue for gynecologic oncological condition
  • Patients who approves Le Fort colpocleisis among who does not have any sexual intercourse
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Lateral suspension

    "Uterus-preserving Laparoscopic lateral suspension with mesh" technique will be performed in this arm.

    Procedure: Uterus-preserving laparoscopic lateral suspension with mesh

  • Experimental
    Sacrocervicopexy

    "Uterus-preserving Laparoscopic sacrocervicopexy with mesh" technique will be performed in this arm.

    Procedure: Uterus-preserving laparoscopic sacrocervicopexy with mesh

Interventions

  • ProcedureUterus-preserving laparoscopic lateral suspension with mesh

    V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.

  • ProcedureUterus-preserving laparoscopic sacrocervicopexy with mesh

    The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.

06

What researchers measure

Primary outcomes

  1. Change from baseline POP-Q measurements (mm) at 12th month.

    Prolapse degree; Point Ba/C/Bp

    Time frame: 12 months for each participant

Secondary outcomes

  1. Subjective Success - Change from baseline Female Sexual Function Index (FSFI) to measure sexual dysfunction at 12th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. The FSFI is a multiple-trait scoring, self-report document used to assess female sexual function. It consists of 19 items that encompass six separate domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The maximum score is 36 points and the minimum score is 2 points. After completion of the questionnaire, the total SF score was calculated as follows: no sexual dysfunction (SD) (≥ 30 points) , mild SD (between \<29 and \> 23 points), and severe SD (≤ 22 points).

    Time frame: 12 months for each participant

  2. Subjective Success - Change from baseline Michigan Incontinence Severity Index (M-ISI) to measure urinary incontinence at 12th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. It has ten items, consisting of a total M-ISI domain (the sum of items 1-8) and a distinct Bother domain (the sum of items 9 and 10). The total M-ISI score consists of three subdomains (items 1-3 for stress urinary incontinence \[SUI\], items 4-6 for UUI, and items 7 and 8 for PU). The responses for each item range from 0 to 4 on a Likert-type scale, with higher values representing greater symptoms and greater bother. The total M-ISI domain ranges from 0 to 32, the Bother domain ranges from 0 to 8, the SUI and UUI subdomains range from 0 to 12, and the PU subdomain ranges from 0 to 8. Total domain and subdomain scores are obtained by simply adding the respective answers. The minimally important difference has been determined for the following domains/subdomains: total M-ISI (4 points), SUI (2 points), UUI (2 points), and PU (1 point).

    Time frame: 12 months for each participant

  3. Subjective Success - Change from baseline Prolapse Quality of Life questionnaire (PQoL) to measure quality of life according to pelvic organ prolapse at 12th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. he questionnaire included 20 questions grouped in sections (domains) related to a particular aspect of quality of life. A total of nine domains covering general health, prolapse impact, role limitations, physical and social limitations, personal relationships, emotional problems, sleep/energy disturbance as well as severity symptoms measurements were defined. Questions regarding bladder, bowel and sexual function were also separately included and validated for reproducibility and internal consistency. Responses ranged from 'none/not at all', through 'slightly/a little' and 'moderately' to 'a lot' to produce a four-point scoring system for each item. Scores in each domain ranged between 0 and 100 with a high total score indicating a greater impairment of quality of life.

    Time frame: 12 months for each participant

  4. Subjective Success - Change from baseline Pelvic Organ Prolapse Symptom Score (POP-SS) to measure quality of life according to pelvic organ prolapse at 12th month.

    Validated into Turkish language form will be used to compare preoperative and postoperative period. Total range scores: 28 (min:0, max:28). Higher values represent a worse outcome.

    Time frame: 12 months for each participant

  5. Subjective Success - Change from baseline Visual Analog Score (VAS) for pain at 12th month.

    Participant describes the pain related to the mesh. The respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain with a format of a horizontal bar.

    Time frame: 12 months for each participant

  6. Change from baseline Pelvic Hiatus measurements (mm) at 12th month.

    Anteroposterior hiatal length (mm)

    Time frame: 12 months for each participant

  7. Change from baseline Pelvic biometry measurements at 12th month.

    Prolapse degree over symphysis pubis (mm) Anterior compartment over 10mm, Posterior compartment over 15 mm are clinically relevant

    Time frame: 12 months for each participant

  8. Change from baseline bladder neck mobility measurements at 12th month.

    Urethral rotation (degree) between rest and valsalva maneuver states

    Time frame: 12 months for each participant

  9. Failure (%)

    Failure is defined by any recurrence of prolapse, mesh erosion and need for additional surgery

    Time frame: 12 months for each participant

  10. Complications

    Perioperative and postoperative complications including Severe bleeding, hematoma, bladder injury, bowel injury, ureter injury, vascular injury, nerve injury, abscess, lower urinary tract infections, mesh extrusion, mesh exposure, prolapse recurrence, De novo SUI/OAB, dyspareunia, pelvic pain

    Time frame: 12 months for each participant

  11. Operation time

    Duration of the operation between the first skin incision and suturing the skin of the trocar entries

    Time frame: Operation time will noted for each participant at the same day of the operation. Operation time will be determined with using a chronometer,from the time of first skin incision until the suturing the skin of the trocar entry, assessed up to 52 weeks.

07

Study locations

2 sites
  • Fatih Sultan Mehmet Training and Research Hospital, Sancaktepe Campus
    Istanbul, Sancaktepe 34785, Turkey
  • Sisli Hamidiye Etfal Training and Research Hospital
    Istanbul, Sisli 34371, Turkey
08

References and documents

Publications

  • Veit-Rubin N, Dubuisson JB, Gayet-Ageron A, Lange S, Eperon I, Dubuisson J. Patient satisfaction after laparoscopic lateral suspension with mesh for pelvic organ prolapse: outcome report of a continuous series of 417 patients. Int Urogynecol J. 2017 Nov;28(11):1685-1693. doi: 10.1007/s00192-017-3327-2. Epub 2017 Apr 17. PubMed 28417156 ↗

Individual participant data

Plan to share: No — Study Protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Mar 2019, 13 months.

Of 37 interventional studies with no phase under Uterine Prolapse, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 68. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2018
First posted
Feb 5, 2018
StartActual
Jan 24, 2018
Primary completionActual
Mar 14, 2019
CompletionActual
Mar 14, 2019
Last update
Mar 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03421457
Responsible party
MURAT YASSA (Principal Investigator, Fatih Sultan Mehmet Training and Research Hospital) — Principal investigator
First posted
Feb 5, 2018
Start date
Jan 24, 2018
Primary completion
Mar 14, 2019
Completion
Mar 14, 2019
Last update
Mar 18, 2019

Study contacts

Niyazi Tug, As.Prof.
study director · Chief of the Department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion